Analysts Set IQVIA Holdings Inc. (NYSE:IQV) Price Target at $226.63

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned an average recommendation of “Buy” from the seventeen brokerages that are currently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $226.6250.

IQV has been the subject of a number of recent research reports. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective for the company in a research report on Friday, March 6th. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and boosted their price objective for the company from $174.00 to $213.00 in a research report on Monday, March 9th. Truist Financial reduced their price target on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 19th. Evercore reissued an “outperform” rating and set a $185.00 price target on shares of IQVIA in a report on Wednesday, April 8th. Finally, BMO Capital Markets set a $250.00 price target on shares of IQVIA in a report on Friday, February 6th.

Hedge Funds Weigh In On IQVIA

Several hedge funds and other institutional investors have recently modified their holdings of IQV. Eubel Brady & Suttman Asset Management Inc. bought a new stake in IQVIA during the 3rd quarter valued at $14,278,000. Eagle Rock Investment Company LLC increased its stake in shares of IQVIA by 33.6% during the third quarter. Eagle Rock Investment Company LLC now owns 46,332 shares of the medical research company’s stock valued at $8,800,000 after acquiring an additional 11,657 shares during the period. OPTIMAS CAPITAL Ltd acquired a new position in shares of IQVIA during the third quarter valued at approximately $4,008,000. EDENTREE ASSET MANAGEMENT Ltd acquired a new position in shares of IQVIA during the third quarter valued at approximately $7,368,000. Finally, Candriam S.C.A. increased its stake in shares of IQVIA by 61.2% during the third quarter. Candriam S.C.A. now owns 272,747 shares of the medical research company’s stock valued at $51,806,000 after acquiring an additional 103,567 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

Shares of NYSE:IQV opened at $160.70 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The firm has a 50-day simple moving average of $170.12 and a 200 day simple moving average of $203.01. The company has a market cap of $27.27 billion, a PE ratio of 20.45, a P/E/G ratio of 1.74 and a beta of 1.39.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, beating analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. During the same quarter in the prior year, the firm earned $3.12 EPS. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, sell-side analysts anticipate that IQVIA will post 11.5 EPS for the current year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.